Reduced prevalence of cardiovascular disease and metabolic syndrome-related disorders among Japanese long-term inpatients with schizophrenia

Purpose: Individuals with schizophrenia have a vastly reduced lifespan compared with the general population; comorbid cardiovascular disease (CVD) is the leading cause of death for them. Furthermore, these individuals are more likely to have metabolic syndrome-related disorders (MSDs), which increas...

Full description

Saved in:
Bibliographic Details
Published inClinical Neuropsychopharmacology and Therapeutics Vol. 6; pp. 16 - 27
Main Authors Saitou, Kenichi, Tani, Masayuki, Kato, Nobumasa, Iwanami, Akira, Yamada, Hiroki, Nakamura, Dan, Takashio, Osamu, Ikeda, Ayumi, Tamura, Toshiyuki, Umezawa, Kaori, Hirata, Yosihito, Morita, Tepei, Inamoto, Atsuko
Format Journal Article
LanguageEnglish
Published The Japanese Society of Clinical Neuropsychopharmacology 2015
Subjects
Online AccessGet full text
ISSN1884-8826
1884-8826
DOI10.5234/cnpt.6.16

Cover

Abstract Purpose: Individuals with schizophrenia have a vastly reduced lifespan compared with the general population; comorbid cardiovascular disease (CVD) is the leading cause of death for them. Furthermore, these individuals are more likely to have metabolic syndrome-related disorders (MSDs), which increase CVD risk. We examined the medical records of long-term inpatients with schizophrenia to identify methods for preventing CVD and MSDs. Method: A retrospective survey was conducted on 56 inpatients with schizophrenia. The prevalence rates of CVD and MSDs among inpatients with schizophrenia were compared with Japanese general population data from the 2010 National Health and Nutrition Examination Survey. Then, we compared the variables influencing CVD and MSDs between first- and second-generation antipsychotic drug groups. Results: The prevalences of hyperlipidemia, diabetes mellitus, hypertension, myocardial infarction, and cerebral hemorrhage among individuals with schizophrenia were lower than those among the Japanese general population. This effect is likely attributable to the nursing care offered to individuals with schizophrenia, which includes dietary advice, moderate exercise support, and body weight and blood pressure measurement. Medication did not correlate with CVD or MSD prevalence. Discussion: Long-term hospitalization appeared to be particularly useful in preventing CVD and MSDs; thus, nursing care equivalent to that provided in hospitals can reduce the prevalence of CVD and MSDs among patients with schizophrenia. Antipsychotic drugs might have only a minor influence on CVD and MSD prevalence with reliable nursing care. Japanese psychiatric personnel should attend to outpatients with schizophrenia, as this population is increasing and receives less care than do inpatients.
AbstractList Purpose: Individuals with schizophrenia have a vastly reduced lifespan compared with the general population; comorbid cardiovascular disease (CVD) is the leading cause of death for them. Furthermore, these individuals are more likely to have metabolic syndrome-related disorders (MSDs), which increase CVD risk. We examined the medical records of long-term inpatients with schizophrenia to identify methods for preventing CVD and MSDs. Method: A retrospective survey was conducted on 56 inpatients with schizophrenia. The prevalence rates of CVD and MSDs among inpatients with schizophrenia were compared with Japanese general population data from the 2010 National Health and Nutrition Examination Survey. Then, we compared the variables influencing CVD and MSDs between first- and second-generation antipsychotic drug groups. Results: The prevalences of hyperlipidemia, diabetes mellitus, hypertension, myocardial infarction, and cerebral hemorrhage among individuals with schizophrenia were lower than those among the Japanese general population. This effect is likely attributable to the nursing care offered to individuals with schizophrenia, which includes dietary advice, moderate exercise support, and body weight and blood pressure measurement. Medication did not correlate with CVD or MSD prevalence. Discussion: Long-term hospitalization appeared to be particularly useful in preventing CVD and MSDs; thus, nursing care equivalent to that provided in hospitals can reduce the prevalence of CVD and MSDs among patients with schizophrenia. Antipsychotic drugs might have only a minor influence on CVD and MSD prevalence with reliable nursing care. Japanese psychiatric personnel should attend to outpatients with schizophrenia, as this population is increasing and receives less care than do inpatients.
Author Saitou, Kenichi
Inamoto, Atsuko
Nakamura, Dan
Tani, Masayuki
Umezawa, Kaori
Takashio, Osamu
Hirata, Yosihito
Yamada, Hiroki
Tamura, Toshiyuki
Iwanami, Akira
Kato, Nobumasa
Ikeda, Ayumi
Morita, Tepei
Author_xml – sequence: 1
  fullname: Saitou, Kenichi
  organization: Department of Psychiatry, Showa University School of Medicine
– sequence: 1
  fullname: Tani, Masayuki
  organization: Department of Psychiatry, Showa University School of Medicine
– sequence: 1
  fullname: Kato, Nobumasa
  organization: Department of Psychiatry, Showa University School of Medicine
– sequence: 1
  fullname: Iwanami, Akira
  organization: Department of Psychiatry, Showa University School of Medicine
– sequence: 1
  fullname: Yamada, Hiroki
  organization: Department of Psychiatry, Showa University School of Medicine
– sequence: 1
  fullname: Nakamura, Dan
  organization: Department of Psychiatry, Showa University School of Medicine
– sequence: 1
  fullname: Takashio, Osamu
  organization: Department of Psychiatry, Showa University School of Medicine
– sequence: 1
  fullname: Ikeda, Ayumi
  organization: Department of Psychiatry, Showa University School of Medicine
– sequence: 1
  fullname: Tamura, Toshiyuki
  organization: Department of Psychiatry, Showa University School of Medicine
– sequence: 1
  fullname: Umezawa, Kaori
  organization: Department of Psychiatry, Showa University School of Medicine
– sequence: 1
  fullname: Hirata, Yosihito
  organization: Department of Psychiatry, Showa University School of Medicine
– sequence: 1
  fullname: Morita, Tepei
  organization: Department of Psychiatry, Showa University School of Medicine
– sequence: 1
  fullname: Inamoto, Atsuko
  organization: Department of Psychiatry, Showa University School of Medicine
BookMark eNp9kMtKBDEQRYMo-Fz4B9kq9Jj0TKd7cCXiE0EQXTc1lWonkk6aJKOM3-BHGx1fK2tTVZdTl-Jus3XnHTG2L8WoKseTI3RDGqmRVGtsSzbNpGiaUq3_mTfZXoxPIlfViCxusbc70gskzYdAz2DJIXHfcYSgjX-GiAsLgWsTCSJxcJr3lGDmrUEel04H31MRyELKHhnzQVOIHHrvHvk1DOAo39m8FYlCz40bIBlyKfIXk-Y84ty8-mEeyBnYZRsd2Eh7X32HPZyf3Z9eFje3F1enJzcFllKqYlbVIHRTNzNFM1SVmFYTpKkqle46ABRYKiWxnop6WosaSxT1OGtEBLKkarzDDle-i_zN8gWsbYdgegjLVor2I8r2I8pWtVJl-GAFY_AxBur-ZY9X7FNM8Eg_JIRk0NI3KT7pX3UOoSU3fge88pIA
Cites_doi 10.1046/j.1440-1614.2001.00877.x
10.1002/14651858
10.1136/bmj.321.7259.483
10.1016/j.schres.2010.07.012
10.1177/070674379103600401
10.1002/hup.932
10.1192/bjp.171.6.502
10.1093/schbul/sbr148
10.1007/s12529-013-9298-x
10.1093/oxfordjournals.schbul.a033504
10.1017/S0033291798008186
10.1176/appi.ajp.2011.10111609
10.1016/j.ahj.2005.02.007
10.1002/14651858.CD005148.pub2
10.1176/appi.ajp.160.2.284
10.1016/j.pnpbp.2012.01.014
10.1192/bjp.183.6.534
10.1016/j.euroneuro.2005.04.009
10.1111/j.1365-2125.2004.02102.x
10.1192/bjp.bp.109.067512
10.1192/bjp.177.3.212
10.1017/S1121189X00000476
10.1192/bjp.188.2.122
10.1291/hypres.28.901
10.2188/jea.JE20130004
ContentType Journal Article
Copyright 2015 The Japanese Society of Clinical Neuropsychopharmacology
Copyright_xml – notice: 2015 The Japanese Society of Clinical Neuropsychopharmacology
DBID AAYXX
CITATION
ADTOC
UNPAY
DOI 10.5234/cnpt.6.16
DatabaseName CrossRef
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
DatabaseTitleList
Database_xml – sequence: 1
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1884-8826
EndPage 27
ExternalDocumentID 10.5234/cnpt.6.16
10_5234_cnpt_6_16
article_cnpt_6_0_6_16_article_char_en
GroupedDBID 53G
ABJNI
ACGFS
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
DIK
JSF
JSH
KQ8
OK1
RJT
RZJ
AAYXX
CITATION
ADTOC
UNPAY
ID FETCH-LOGICAL-c2116-b57a0d878b6ebc650954ce9626dffaac0c2661c79079707c2c073c26eeea12e53
IEDL.DBID UNPAY
ISSN 1884-8826
IngestDate Tue Aug 19 20:50:13 EDT 2025
Tue Jul 01 03:05:36 EDT 2025
Wed Sep 03 06:30:00 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2116-b57a0d878b6ebc650954ce9626dffaac0c2661c79079707c2c073c26eeea12e53
OpenAccessLink https://proxy.k.utb.cz/login?url=https://www.jstage.jst.go.jp/article/cnpt/6/0/6_16/_pdf
PageCount 12
ParticipantIDs unpaywall_primary_10_5234_cnpt_6_16
crossref_primary_10_5234_cnpt_6_16
jstage_primary_article_cnpt_6_0_6_16_article_char_en
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015
PublicationDateYYYYMMDD 2015-01-01
PublicationDate_xml – year: 2015
  text: 2015
PublicationDecade 2010
PublicationTitle Clinical Neuropsychopharmacology and Therapeutics
PublicationTitleAlternate CNPT
PublicationYear 2015
Publisher The Japanese Society of Clinical Neuropsychopharmacology
Publisher_xml – name: The Japanese Society of Clinical Neuropsychopharmacology
References [14] Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697-701.
[6] Casadebaig F, Philippe A. Mortality in schizophrenia patients. 3 years follow-up of a cohort. L'Encephale 1999; 25: 329-337.
[7] Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115-1121.
[18] Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123: 225-233.
[28] Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007; 1: CD005148. doi:10.1002/14651858.CD005148.pub2
[23] Tatsumi Y, Watanabe M, Kokubo Y, Nishimura K, Higashiyama A, Okamura T, Okayama A, Miyamoto Y. Effect of age on the association between waist-to-height ratio and incidence of cardiovascular disease: the Suita study. J Epidemiol 2013; 23: 351-359.
[17] Ryan M, Collins P, Thakore J. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160; 284-289.
[4] Ösby U, Correia N, Hammar N, Brandt L, Wicks S, Ekbom A, Sparén P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 2000; 321: 483-484.
[8] Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502-508.
[22] Sairenchi T, Iso H, Irie F, Fukasawa N, Yamagishi K, Kanashiki M, Saito Y, Ota H, Nose T. Age-specific relationship between blood pressure and the risk of total and cardiovascular mortality in Japanese men and women. Hypertens Res 2005; 28: 901-909.
[9] Lisa D, Peter W, Janine D, Richard G, Leticia P, Alicia L, Anthony L. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26: 903-1012.
[20] Jerrell JM, McIntyre RS. Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol 2008; 23: 283-290.
[2] Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005; 15: 399-409.
[10] Kubo S, Kotorii T. Systematic intervention for obesity and dyslipidemia in patients with schizophrenia. Jpn J Clin Psychopharmacol 2014;29: 219-224.
[13] McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003; 183: 534-539.
[27] Gorczynski P, Faulkner G. Exercise therapy for schizophrenia. Cochrane Database Syst Rev 2010; 5: CD004412. doi:10.1002/14651858. CD004412.pub2
[5] Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36: 239-245.
[1] Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-217.
[29] Inagaki A, Tomita M. Novel antipsychotics, antipsychotic polypharmacy and high dose treatment in Japan. Jpn J Clin Psychopharm 2003; 6: 391-401.
[16] Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry 2001; 35: 196-202.
[25] Kurosawa M, Tensho M, Tanifuji H, Kato T, Uno J, Umeda K, Miwa T, Noda Y, Yoshio T. Prescription survey 2011 of inpatients with schizophrenia in Japan: examination about the new investigation items of BMI and abnormal ECG. Jpn Clin Psychopharmacol 2013; 16: 1041-1050.
[11] Mitchell AJ, Vacampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr Bull Published online December 29, 2011; doi: 10.1093/schbul/sbr148.
[3] Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010; 196: 116-121.
[24] Mikami T, Suzuki U, Tajiri M. Kunizuka T, Abe H, Someya T. Effect of admission to the psychiatric ward on the body weight and glucose metabolism of patients with schizophrenia. Jpn J Clin Psychopharmacol 2012; 15: 1857-1862.
[15] Gurpegui M, Martínez-Ortega JM, Gutiérrez-Rojas L, Rivero J, Rojas C, Jurado D. Oveweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. Prog Neuro-Psychopharmacol Biol Psychiatry 2012; 37: 169-175.
[12] Gupita A, Craig TK. Diet, smoking and cardiovascular risk in schizophrenia in high and low care supported housing. Epidemiol Psichiatr Soc 2009; 18: 200-207.
[21] Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006; 188: 122-127.
[30] Sim K, Su A, Fujii S, Yang SY, Chong MY, Unqvari GS, Si T, Chung EK, Tsang HY, Chan YH, Heckers S, Shinfuku N, Tan CH. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004; 58: 178-183.
[19] Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011; 168: 947-956.
[26] Stanley S, Laugharne J. The impact of lifestyle factors on the physical health of people with a mental illness: a brief review. Int J Behav Med 2014; 21: 275-281.
22
23
24
25
26
27
28
29
30
10
11
12
13
14
15
16
17
18
19
1
2
3
4
5
6
7
8
9
20
21
References_xml – reference: [25] Kurosawa M, Tensho M, Tanifuji H, Kato T, Uno J, Umeda K, Miwa T, Noda Y, Yoshio T. Prescription survey 2011 of inpatients with schizophrenia in Japan: examination about the new investigation items of BMI and abnormal ECG. Jpn Clin Psychopharmacol 2013; 16: 1041-1050.
– reference: [7] Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115-1121.
– reference: [29] Inagaki A, Tomita M. Novel antipsychotics, antipsychotic polypharmacy and high dose treatment in Japan. Jpn J Clin Psychopharm 2003; 6: 391-401.
– reference: [3] Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010; 196: 116-121.
– reference: [8] Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502-508.
– reference: [19] Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011; 168: 947-956.
– reference: [28] Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007; 1: CD005148. doi:10.1002/14651858.CD005148.pub2
– reference: [20] Jerrell JM, McIntyre RS. Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol 2008; 23: 283-290.
– reference: [23] Tatsumi Y, Watanabe M, Kokubo Y, Nishimura K, Higashiyama A, Okamura T, Okayama A, Miyamoto Y. Effect of age on the association between waist-to-height ratio and incidence of cardiovascular disease: the Suita study. J Epidemiol 2013; 23: 351-359.
– reference: [12] Gupita A, Craig TK. Diet, smoking and cardiovascular risk in schizophrenia in high and low care supported housing. Epidemiol Psichiatr Soc 2009; 18: 200-207.
– reference: [5] Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36: 239-245.
– reference: [17] Ryan M, Collins P, Thakore J. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160; 284-289.
– reference: [9] Lisa D, Peter W, Janine D, Richard G, Leticia P, Alicia L, Anthony L. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26: 903-1012.
– reference: [13] McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003; 183: 534-539.
– reference: [2] Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005; 15: 399-409.
– reference: [21] Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006; 188: 122-127.
– reference: [18] Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123: 225-233.
– reference: [22] Sairenchi T, Iso H, Irie F, Fukasawa N, Yamagishi K, Kanashiki M, Saito Y, Ota H, Nose T. Age-specific relationship between blood pressure and the risk of total and cardiovascular mortality in Japanese men and women. Hypertens Res 2005; 28: 901-909.
– reference: [6] Casadebaig F, Philippe A. Mortality in schizophrenia patients. 3 years follow-up of a cohort. L'Encephale 1999; 25: 329-337.
– reference: [24] Mikami T, Suzuki U, Tajiri M. Kunizuka T, Abe H, Someya T. Effect of admission to the psychiatric ward on the body weight and glucose metabolism of patients with schizophrenia. Jpn J Clin Psychopharmacol 2012; 15: 1857-1862.
– reference: [1] Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-217.
– reference: [26] Stanley S, Laugharne J. The impact of lifestyle factors on the physical health of people with a mental illness: a brief review. Int J Behav Med 2014; 21: 275-281.
– reference: [30] Sim K, Su A, Fujii S, Yang SY, Chong MY, Unqvari GS, Si T, Chung EK, Tsang HY, Chan YH, Heckers S, Shinfuku N, Tan CH. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004; 58: 178-183.
– reference: [16] Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry 2001; 35: 196-202.
– reference: [14] Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697-701.
– reference: [11] Mitchell AJ, Vacampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr Bull Published online December 29, 2011; doi: 10.1093/schbul/sbr148.
– reference: [10] Kubo S, Kotorii T. Systematic intervention for obesity and dyslipidemia in patients with schizophrenia. Jpn J Clin Psychopharmacol 2014;29: 219-224.
– reference: [27] Gorczynski P, Faulkner G. Exercise therapy for schizophrenia. Cochrane Database Syst Rev 2010; 5: CD004412. doi:10.1002/14651858. CD004412.pub2
– reference: [4] Ösby U, Correia N, Hammar N, Brandt L, Wicks S, Ekbom A, Sparén P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 2000; 321: 483-484.
– reference: [15] Gurpegui M, Martínez-Ortega JM, Gutiérrez-Rojas L, Rivero J, Rojas C, Jurado D. Oveweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. Prog Neuro-Psychopharmacol Biol Psychiatry 2012; 37: 169-175.
– ident: 16
  doi: 10.1046/j.1440-1614.2001.00877.x
– ident: 27
  doi: 10.1002/14651858
– ident: 4
  doi: 10.1136/bmj.321.7259.483
– ident: 18
  doi: 10.1016/j.schres.2010.07.012
– ident: 5
  doi: 10.1177/070674379103600401
– ident: 20
  doi: 10.1002/hup.932
– ident: 10
– ident: 8
  doi: 10.1192/bjp.171.6.502
– ident: 11
  doi: 10.1093/schbul/sbr148
– ident: 26
  doi: 10.1007/s12529-013-9298-x
– ident: 9
  doi: 10.1093/oxfordjournals.schbul.a033504
– ident: 14
  doi: 10.1017/S0033291798008186
– ident: 19
  doi: 10.1176/appi.ajp.2011.10111609
– ident: 7
  doi: 10.1016/j.ahj.2005.02.007
– ident: 28
  doi: 10.1002/14651858.CD005148.pub2
– ident: 24
– ident: 17
  doi: 10.1176/appi.ajp.160.2.284
– ident: 15
  doi: 10.1016/j.pnpbp.2012.01.014
– ident: 13
  doi: 10.1192/bjp.183.6.534
– ident: 2
  doi: 10.1016/j.euroneuro.2005.04.009
– ident: 30
  doi: 10.1111/j.1365-2125.2004.02102.x
– ident: 29
– ident: 3
  doi: 10.1192/bjp.bp.109.067512
– ident: 1
  doi: 10.1192/bjp.177.3.212
– ident: 12
  doi: 10.1017/S1121189X00000476
– ident: 21
  doi: 10.1192/bjp.188.2.122
– ident: 22
  doi: 10.1291/hypres.28.901
– ident: 6
– ident: 23
  doi: 10.2188/jea.JE20130004
– ident: 25
SSID ssj0000580884
Score 1.5549601
Snippet Purpose: Individuals with schizophrenia have a vastly reduced lifespan compared with the general population; comorbid cardiovascular disease (CVD) is the...
SourceID unpaywall
crossref
jstage
SourceType Open Access Repository
Index Database
Publisher
StartPage 16
SubjectTerms antipsychotic drugs
cardiovascular disease
metabolic syndrome-related disorders
nursing care
schizophrenia
Title Reduced prevalence of cardiovascular disease and metabolic syndrome-related disorders among Japanese long-term inpatients with schizophrenia
URI https://www.jstage.jst.go.jp/article/cnpt/6/0/6_16/_article/-char/en
https://www.jstage.jst.go.jp/article/cnpt/6/0/6_16/_pdf
UnpaywallVersion publishedVersion
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Clinical Neuropsychopharmacology and Therapeutics, 2015, Vol.6, pp.16-27
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1884-8826
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000580884
  issn: 1884-8826
  databaseCode: KQ8
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1884-8826
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000580884
  issn: 1884-8826
  databaseCode: DIK
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_WdLDtYd1Hy7Kt5ehGnyrHSSTZeSxjpXSspKOB7MnI-ihtM8fUDiP7G_ZH7xQrTVoYjD0Zm7Ms7oTufufT7wA-GicMuVnOVNcmjEsTM0UogClnyBvapK-VT-h_PZMnI346FuOQuqhCWeU1xUWX1l-iy2l0XXaCEju6KOuOJBQvs67sZKVxG7ApBQXhLdgcnQ2Pvnt4laacUdwoGx4hAlp88WIkI9_UfM37PG4-9AyezIpSzX-qyWTNtxxvwXg5q6ak5Caa1Xmkfz0gbPyPab-A5yHexKNG6CU8ssUrOBg2hNXzQ7xYnb-qDvEAhysq6_lr-P3NM7tag-WtpwX3uwBOHep7RawYfvKgKgz-sDUtq8mVxiUXAlscl6ExTCD6rHDR4QhPyU_7_pc4oTvmXQReFYHntUKfIMZqvSRwG0bHny8-nbDQv4FpgpWS5SJRsUmTNJc2156qT3BtBwShjHNK6Vj76EAnhM8HSZzonqb9hp5Za1W3Z0V_B1rFtLBvAFOrCMj1jLJCcpmLPMmdlTwVjuuB68s27C_tmpUNTUdG8MYbP_Pqz7zq28AbG92JBAstReKF2OopaZw2jzZ8uFsffx_87T9JvYOnFHGJJofzHlr17czuUlRT53uw8eU83Qvr-A9BTQOY
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-2dLDtod1Hx9KPcbSjT5XjJJLsPJbSUgorYTSQPRlZH6Vt6pjaYWR_w_7onWKlyQaDsSdjc5bFndDd73z6HcBn44QhN8uZ6tqEcWlipggFMOUMeUOb9LXyCf0vV_JixC_HYhxSF1Uoq7yjuOjG-kt0M43uyk5QYkcXZd2RhOJl1pWdrDTuOWxIQUF4CzZGV8OTbx5epSlnFDfKhkeIgBZfvBjJyDc1X_M-L5oPvYaXs6JU8-9qMlnzLedbMF7OqikpuY9mdR7pH38QNv7HtN_AZog38aQRegvPbPEOjoYNYfX8GK9X56-qYzzC4YrKev4efn71zK7WYPnoacH9LoBTh_q3IlYMP3lQFQYfbE3LanKrccmFwBbHZWgME4g-K1x0OMJL8tO-_yVO6I55F4G3ReB5rdAniLFaLwnchtH52fXpBQv9G5gmWClZLhIVmzRJc2lz7an6BNd2QBDKOKeUjrWPDnRC-HyQxInuadpv6Jm1VnV7VvQ_QKuYFvYjYGoVAbmeUVZILnORJ7mzkqfCcT1wfdmGg6Vds7Kh6cgI3njjZ179mVd9G3hjoyeRYKGlSLwQWz0ljdPm0YbDp_Xx98F3_klqF15RxCWaHM4etOrHmd2nqKbOP4UV_AsxeAKj
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reduced+prevalence+of+cardiovascular+disease+and+metabolic+syndrome-related+disorders+among+Japanese+long-term+inpatients+with+schizophrenia&rft.jtitle=Clinical+Neuropsychopharmacology+and+Therapeutics&rft.au=Saitou%2C+Kenichi&rft.au=Tani%2C+Masayuki&rft.au=Kato%2C+Nobumasa&rft.au=Iwanami%2C+Akira&rft.date=2015&rft.pub=The+Japanese+Society+of+Clinical+Neuropsychopharmacology&rft.eissn=1884-8826&rft.volume=6&rft.spage=16&rft.epage=27&rft_id=info:doi/10.5234%2Fcnpt.6.16&rft.externalDocID=article_cnpt_6_0_6_16_article_char_en
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1884-8826&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1884-8826&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1884-8826&client=summon